Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04105699 · ClinicalTrials.gov registry record
Evaluation of Immunoassay Measurements of Pancreatic Stone Protein Performed on abioSCOPE® Device With the PSP Assay on ICU Patients at Risk of Sepsis as an Aid in Identifying Sepsis
A clinical trial of Sepsis, sponsored by Abionic.
- Completed
- Registry status
- 544
- Enrollment target
- 5
- Study locations
NCT04105699: Completed study of Sepsis, sponsored by Abionic.
NCT04105699 is a study of Sepsis that has completed, run by Abionic. The registered enrollment target is 544 participants, below the 6,559-participant average among 90 other Sepsis trials with a reported enrollment target (92% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04105699, a study of Sepsis, has completed, sponsored by Abionic.
- COMPLETED
- Registry status
- 544 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a multicenter, prospective, biomarker-result-blinded observational study evaluating immunoassay measurements of pancreatic stone protein (PSP) performed on Abionic's abioSCOPE device with the PSP assay on ICU patients at risk of sepsis as an aid in identifying sepsis.
Primary Outcome
Assess the clinical sensitivity and specificity of the abioSCOPE PSP assay obtained on day 1 of ICU stay to identify sepsis within 3 days, based on EIRC assessment of sepsis.
Conditions Studied
Interventions
- DEVICE Blood sampling
Study Locations (5)
Illinois
- Northwestern University - Chicago
- Rush University Medical Center - Chicago
Kentucky
- University of Kentucky - Lexington
Ohio
- Mercy Health St. Vincent - Toledo
Rhode Island
- Rhode Island Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 544 participants |
| Start Date | 2019-12-10 |
| Est. Completion | 2023-12-28 |
What the finished NCT04105699 record still lists
NCT04105699 is an observational study that tracks outcomes without assigning an intervention. The registered 544 participants enrollment target is mid-sized for trials with a published cap, below the 6,559-participant average among 90 other Sepsis trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Sepsis appearing as the primary indexed condition, and to 1 intervention - of which Blood sampling is the first listed.
NCT04105699 lists 5 locations in 4 states (Illinois, Kentucky, Ohio).
Frequently Asked Questions
What is clinical trial NCT04105699 about?
NCT04105699 is a clinical study titled "Evaluation of Immunoassay Measurements of Pancreatic Stone Protein Performed on abioSCOPE® Device With the PSP Assay on ICU Patients at Risk of Sepsis as an Aid in Identifying Sepsis". This is a multicenter, prospective, biomarker-result-blinded observational study evaluating immunoassay measurements of pancreatic stone protein (PSP) performed on Abionic's abioSCOPE device with the PSP assay on ICU patients at risk of sepsis as an aid in identifying sepsis.
What is the current status of trial NCT04105699?
This trial is currently completed. The enrollment target is 544 participants. The study started on 2019-12-10. Estimated completion is 2023-12-28.
What conditions does trial NCT04105699 study?
This clinical trial studies the following conditions: Sepsis.
What interventions are being tested in trial NCT04105699?
The interventions under investigation include: Blood sampling (DEVICE).
Who is sponsoring clinical trial NCT04105699?
This trial is sponsored by Abionic, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04105699 being conducted?
This trial has 5 study locations across Illinois, Kentucky, Ohio, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04105699's enrollment target sits among peer trials
544 22nd of 90 higher than 69 of 90 other Sepsis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The APS Phenotyping Study
RECRUITING
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
Renin Angiotensin Aldosterone System In Septic Kids
RECRUITING
-
The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls
RECRUITING · NA
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03127761 · 544 participants
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
- NCT04378790 · 544 participants · Phase 3
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
- NCT06118502 · 544 participants · NA
A Clinical Trial of Adaptive Treatment for Early Smoking Cessation Relapse
- NCT06170437 · 544 participants · NA
Smoke-free Home Study in Subsidized Housing
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI